The first sub unit vaccine being investigated by N4 Pharma is a single dose reformulation of the existing Hepatitis B surface antigen vaccine (HBsAg) which had annual sales of approximately $920 million in 2012. The N4 Pharma Directors believe there is a commercial need for a single dose Hepatitis B vaccine. Nuvac is being used to develop this by reformulating the existing HBsAg vaccine.
N4 Pharma is investigating the use of its Nuvec technology in the field of cancer vaccines. Global revenues for the cancer vaccines market are forecast by Global Business Intelligence in their November report “Global Cancer Vaccines Market to 2022” to grow at a CAGR of 16.9 per cent., from $2.5 billion in 2015 to $7.5 billion in 2022. The cancer vaccine pipeline is large with 1,286 products in development in November 2016. This represents a significant market opportunity for Nuvec. The N4 Pharma Directors believe that once the ‘proof of concept’ data pack has been developed for Nuvec, which is expected to be completed within the next 12 months, business development will commence to establish collaborative research projects with potential partners.